

PNEUMOCOCCAL VACCINE

Indications/Uses

Active immunisation against pneumococcal disease.

Dosage/Direction for Use

Adult : IM As 13- or 23-valent conjugate vaccine: Primary immunisation: 0.5 mL as a single dose. SC As 23-valent conjugate vaccine: Primary immunisation: 0.5 mL as a single dose.

Dosage Details

Intramuscular

Active immunisation against pneumococcal disease

Adult: As 13-valent conjugate vaccine: Primary immunisation: 0.5 mL as a single dose.

Child: As 10- or 13-valent conjugate vaccine: Primary immunisation: 6 weeks to 5 years 3 doses of 0.5 mL given at least 1 month apart. Booster dose given between 12-15 months of age or at least 6 months after the last dose. Alternatively, 2 doses of 0.5 mL given at 6 weeks of age, then 2nd dose given 2 months later. Booster dose given between 12-15 months of age or at least 6 months after the last dose. In unvaccinated infants and children: 7-11 months 2 doses of 0.5 mL give at least 1 month apart. 3rd dose at 2 years of age; 2-23 months 2 doses of 0.5 mL give at least 2 months apart; 2-17 years Same as adult dose.

Intramuscular, Subcutaneous

Active immunisation against pneumococcal disease

Adult: As 23-valent conjugate vaccine: Primary immunisation: 0.5 mL as a single dose via IM or SC inj. Revaccination may be considered for persons with increased risk.

Child: As 23-valent conjugate vaccine: ≥ 2 years Same as adult dose.

Contraindications

Hypersensitivity.

Special Precautions

Patient with history of coagulation disorders (including thrombocytopenia), severe CV and pulmonary dysfunction, immunosuppression. Postpone vaccination in patients with moderate or severe acute febrile illness. Not indicated for treatment of pneumococcal infections. Renal and hepatic impairment. Children. Pregnancy and lactation.

Adverse Reactions

Significant: Inj site reactions (e.g. pain, redness, bruising, swelling, induration); hypersensitivity reactions, fever, syncope, headache, rash.

General disorders and administration site conditions: Irritability, fatigue.

Metabolism and nutrition disorders: Decreased appetite.

Musculoskeletal and connective tissue disorders: Chills, myalgia, arthralgia.

Psychiatric disorders: Somnolence, insomnia.

Pregnancy Category (US FDA)

IM/Parenteral/SC: C

Patient Counseling Information

This drug may cause syncope, if affected, do not drive or operate machinery.

MonitoringParameters

Monitor for hypersensitivity reactions 15 minutes after administration. Antibiotic prophylaxis should be continued after vaccination.

Drug Interactions

Increased risk of bleeding with anticoagulants. Decreased immune response with immunosuppressive therapies (e.g. high dose corticosteroids).

Action

Description: Pneumococcal vaccine, an inactive bacterial vaccine, contains purified capsular polysaccharides of pneumococcal serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F that promotes active immunisation against diseases caused by these *S. pneumoniae* serotypes.

Onset: Immunity: Approx 2-3 weeks.

Duration: At least 5 years.

Storage

Store between 2-8°C. Do not freeze. Protect from light. Any unused portions should be disposed of in accordance with local requirements.

MIMS Class

Vaccines, Antisera & Immunologicals

ATC Classification

J07AL - Pneumococcal vaccines ; Used for active immunizations.